Is investment in personalized medicine worthwhile?
Nowakowska, Elżbieta ; Metelska, Jana ; Matschay, Arleta ; Burda, Kinga ; Czubak, Anna ; Kus, Krzysztof
Komitet Biotechnologii PAN ; Instytut Chemii Bioorganicznej PAN
Monografia opublikowana w zeszycie Biotechnologia 2(85)'2009
Since the dawn of the 21st century, pharmacology has become a field increasingly closely related to the development of a new science - genomics. Due to increasingly smaller efficacy of using “conventional” therapies, the world of science is starting to seek drugs dedicated to patients with a specific genotype. The possibility of finding the genetic background of diseases largely incurable to this date, such as cancers, diabetes or depression, will allow for “targeted therapy”, improving thereby therapy efficacy by adjusting optimum treatment agents to the individual genetic profile of a specific patient. With propagation of this new type of medicine - personalized medicine, the approach to therapy and the attitude of the patient himself are changing, as the patient seeing efficacy of his therapy is more willing to closely cooperate with the managing physician. Considerations discussed therein allow for a conclusion that further pharmacogenetic research is necessary not only to improve therapy efficacy, but also to seek possibilities of reasonable cost savings in medicine.
2009 ; Biotechnologia 5 (2009)-.
0860-7796 ; oai:rcin.org.pl:72687 ; IChB B-80
Biblioteka Instytutu Chemii Bioorganicznej PAN
Licencja Creative Commons Uznanie autorstwa-Na tych samych warunkach 4.0
Instytut Chemii Bioorganiczneji Polskiej Akademii Nauk
Instytut Chemii Bioorganiczneji Polskiej Akademii Nauk
2 paź 2020
12 cze 2019
149
https://rcin.org.pl/publication/94568
Nazwa wydania | Data |
---|---|
Czy warto inwestować w medycynę personalizowaną? | 2 paź 2020 |
Borkowska, Bożenna
Ziółkowski, Piotr Babula- Skowrońska, Danuta Kaczmarek, Małgorzata Cieśla, Agata Sadowski, Jan
Halota, Waldemar
Wysocki, Piotr J. Handschuh, Paweł Mackiewicz, Andrzej